Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

Restoration & Update

16 Jan 2024 07:00

RNS Number : 7777Z
Microsaic Systems plc
16 January 2024
 

16 January 2024

Microsaic Systems plc

("Microsaic" or the "Company")

 

Restoration of Company's Shares to Trading on AIM,Admission of Placing Shares

and TVR Update

 

Capitalised terms in this announcement carry the same meaning as in the Circularor subsequent announcements, unless the context indicates otherwise

 

Microsaic Systems plc (AIM: MSYS), the developer of micro-electronic instruments and analytical solutions, announce the following updates.

 

Restoration

 

Following the publication of the Annual Report and Interim Results at 7.00 a.m. this morning, its Ordinary Shares are expected to be restored to trading on AIM at 7.30 a.m. today.

 

Admission of Placing Shares & Directors' Participation

 

The Company confirms that the 169,000,000 Placing Shares are expected to be admitted to trading on AIM at 8.00 a.m. today.

 

In addition, following the publication of the Annual Report and Interim Results, the Company confirms that Bob Moore and Nigel Burton have now entered into contractual obligations to subscribe for 9,040,000 and 2,000,000 Placing Shares respectively, in line with the expectations set out in the Conditional Placing announcement issued yesterday afternoon.

 

Total voting rights

 

Following Admission, the Company will have 179,178,185 Ordinary Shares in issue. The Company does not hold any shares in treasury. Therefore, from Admission, the total voting rights in the Company will be 179,178,185.

 

From Admission, the figure of 179,178,185 may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the share capital of the Company pursuant to the FCA's Disclosure Guidance and Transparency Rules.

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a Regulatory Information Service, this information is considered to be in the public domain.

 

Enquiries:

Microsaic Systems plc

Bob Moore, Acting Executive Chairman

+44 (0) 20 3657 0050

via TPI

 

 

Singer Capital Markets(Nominated Adviser & Joint Broker)

Aubrey Powell / Angus Campbell / Oliver Platts

+44 (0)20 7496 3000

 

 

Turner Pope Investments (TPI) Limited(Joint Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

 

About Microsaic Systems

Microsaic has over 20 years' experience in microelectronics and development of instrumentation. The Company has a robust and innovative patent portfolio in cutting-edge technology designed and developed for "Industry 4.0" application serving markets in diversified Industries, Human and Environmental Health. Microsaic's system solutions have enabled analytical detection and characterisation at the point-of-need, whether within a conventional laboratory setting, or within a bioprocessing facility for continuous detection of data at multiple steps in the process workflow.

 

Microsaic's products and solutions are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point-of-need applications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCZZGMMZVLGDZG
Date   Source Headline
24th Nov 20222:00 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
13th Sep 20227:25 amRNSSupply of mass spectroscopy services to DeepVerge
22nd Aug 20227:00 amRNSPartnership with Kingfield Electronics
5th Jul 20224:41 pmRNSSecond Price Monitoring Extn
5th Jul 20224:35 pmRNSPrice Monitoring Extension
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:01 pmRNSPrice Monitoring Extension
4th Jul 20224:43 pmRNSReplacement: Trading Update
1st Jul 20222:09 pmRNSHolding(s) in Company
30th Jun 202212:11 pmRNSResult of AGM
30th Jun 20227:00 amRNSTrading Update
1st Jun 20227:00 amRNSPosting of Annual Report & Notice of AGM
30th May 20227:00 amRNSFinal Results
19th Apr 20227:00 amRNSManufacturing Services Framework Agreement
28th Mar 20227:30 amRNSUpdate on Microsaic's miniaturised technology
15th Mar 20227:00 amRNSBoard Appointment and Strategic Update
8th Mar 20224:35 pmRNSPrice Monitoring Extension
7th Mar 20222:05 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
21st Feb 20221:31 pmRNSHolding(s) in Company
17th Feb 20222:45 pmRNSHolding(s) in Company
16th Feb 202211:06 amRNSSecond Price Monitoring Extn
16th Feb 202211:00 amRNSPrice Monitoring Extension
14th Feb 20227:00 amRNSDirector Dealing, Issue of Equity and TVR
28th Jan 20227:00 amRNSResignation of Chief Executive Officer
12th Jan 20224:43 pmRNSHolding(s) in Company
10th Jan 20223:30 pmRNSInvestor Presentation
10th Jan 20227:00 amRNSTrading Update
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSFurther order from DeepVerge
12th Nov 20217:00 amRNSNew compact screening platform
5th Nov 202110:12 amRNSHolding(s) in Company
27th Oct 20217:00 amRNSLaunch of technology for scaling drug manufacture
22nd Oct 20217:00 amRNSBoard Change
21st Oct 20217:00 amRNSUpdate on DeepVerge Collaboration
28th Sep 20214:30 pmRNSHolding(s) in Company
27th Sep 20217:00 amRNSInterim Results
24th Sep 20217:00 amRNSSigning of agreement to support China operations
22nd Sep 202111:06 amRNSNotice of Results and Investor Presentation
27th Aug 20214:40 pmRNSSecond Price Monitoring Extn
27th Aug 20214:35 pmRNSPrice Monitoring Extension
23rd Aug 20217:00 amRNSDeepVerge Collaboration for Water & Soil Analysis
9th Aug 20217:00 amRNSHeads of Terms signed with manufacturer in China
6th Jul 202111:55 amRNSInvestor Presentation
6th Jul 20217:00 amRNSTrading update for H1 2021
5th Jul 20219:50 amRNSHolding(s) in Company
2nd Jul 20217:00 amRNSDevelopment of real-time monitoring solution
17th Jun 202110:54 amRNSResult of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.